Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 6th 2014

Implications of the Health Insurance Exchange Marketplace and State Law Trends on Commercial Pharmacy

Presenters in this talk focused on how the creation of health insurance exchanges (HIEs) and other federal and state regulations will impact the provision and administration of pharmacy benefits.

February 6th 2014

Healthcare Industry Transformation to Meet Employer Demand for Managing Specialty Pharmacy Costs

According to Howard K. Crowley, head of pharmacy strategic initiatives, Aetna Pharmacy Management, a Towers Watson/ National Business Group on Health survey found that 29% of employers rank the rising costs of specialty drugs as a top challenge to keeping health benefit coverage affordable.

February 5th 2014

Pharmacy Benefit Management Institute Conference Highlights - Part 2

Katie Sullivan

This week AJMC is covering session highlights from the PBMI Annual Drug Benefit conference.

January 30th 2014

Chris Belmont Discusses How Hospitals Manage Health Information

Chris Belmont, vice president and chief information officer, MD Anderson Cancer Center, says the right timing and the right context are essential to effective health data management.

January 28th 2014

Karen Lewis, MS, MM, CGC, Discusses Oncology and Genetic Testing

Karen Lewis, MS, MM, CGC, says the goals of Healthy People 2020 are developed by looking at a variety of key areas in healthcare, and then choosing the most actionable items to improve the overall health of the general population.

January 27th 2014

Doctors, Older Patients Rethink Cancer Treatments

Experts in treating older cancer patients say it's important to think of each patient individually, not to assume that because someone has reached a certain age that he or she isn't going to be able to withstand surgeries, radiation or chemotherapy.

January 23rd 2014

COA and ASCO Issue Joint Statement on Oncology Payment Reform

COA and ASCO are issuing a joint statement on payment reform in cancer care. The goal is to improve the lives of individuals with cancer, in part by developing and supporting payment systems based on evidence-based medicine and measures of quality and value in cancer care.

January 22nd 2014

Drugmakers See Innovation Justifying Further Price Rises

As U.S. consumers are asked to shoulder more prescription drug costs, drugmakers say prices for brand-name medicines will keep rising, mainly because use of their products reduces other healthcare costs.

January 21st 2014

Amy Berman, BS, RN, Discusses Patient-Centered Oncology Care

Amy Berman, BS, RN, says that all too often, people end up in the hospital because they don't know where else to go for treatment.

January 17th 2014

Custom-Fit Treatments for Prostate Cancer

In a bid to improve treatment for men with high-risk prostate cancer, some researchers want to take a page from the playbook for breast cancer.

January 16th 2014

Scott Ramsey, MD, PhD, on Health Economics and Outcomes Research in Oncology

Scott Ramsey, MD, PhD, Fred Hutchinson Cancer Research Center, says that right now, only a small portion of health economics and outcomes research (HEOR) fits into the oncology model.

January 13th 2014

Comorbidities and Cardiovascular Disease Risk in Older Breast Cancer Survivors

Reina Haque, PhD, MPH Marianne Prout, MD Ann M. Geiger, PhD Aruna Kamineni, PhD Soe Soe Thwin, PhD Chantal Avila, MA Rebecca A. Silliman, MD, PhD Virginia Quinn, PhD Marianne Ulcickas Yood, DSc

Effective management of the comorbidities of diabetes and hypertension may increase survival in older breast cancer survivors.

January 10th 2014

For High-Risk Women, Some Breast Cancer Drugs To Be Free

Starting next September, women at increased risk for breast cancer will be able to get some drugs shown to help prevent the disease without a co-pay, the Obama administration said Thursday.

January 2nd 2014

Segment 8 - Treatment's Financial Constraints

The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.

January 2nd 2014

Segment 7 - Cost Considerations

Dr Peskin begins by stating, costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US, including various national organizations.

January 2nd 2014

Segment 5 - Value-based Decisions in NSCLC

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of high value, cost-conscious, cost-aware care.

December 31st 2013

Healthcare Headlines in 2013

Katie Sullivan

A look back at some of the InFocus blog highlights of 2013.

December 30th 2013

Segment 4 - Screening

Panelists discuss screening recommendations and guidelines, including considerations for screening those patients with a smoking history.

December 30th 2013

Segment 3 - Treatment Considerations

The panelists weigh in on the appropriate standards for treating patients with NSCLC.

December 30th 2013

Segment 2 - Histology, Targeted Therapy and Surgery

Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.

December 30th 2013

Segment 1 - Introduction to NSCLC

Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC).

December 30th 2013

For Cancer Survivors, 2014 Will Be the Year to Plan

The coming year will be one for those who have beaten cancer to develop survivorship plans, with the Commission on Cancer to require planning by treatment centers starting in 2015.

December 28th 2013

Discussion 8: Redefining the Role of Industry in Contemporary Healthcare

Cliff Goodman, PhD John L. Fox, MD, MHA Bo Gamble

The final panel of the conference analyzes the role of the industry in healthcare, including panelists' observations on topics such as innovation. Mr Gamble, for instance, offers his insights as to how groups like the Community Oncology Alliance are working with the industry to drive the message about the quality and the value component throughout all the stakeholders. Dr Fox provides perspective on how payers can offer valuable partnerships throughout the industry, including those with pharmaceutical companies.

December 28th 2013

Discussion 7: Value-Based Pricing: The Role of Outcomes Data in Pricing Models

Cliff Goodman, PhD Jeffrey D. Dunn, PharmD, MBA Michael E. Chernew, PhD Kirby Eng, RPh

Dr Cliff Goodman leads a discussion featuring panelists including The American Journal of Managed Care's co-editor-in-chief, Dr Michael Chernew. Topics of the discussion include the impact of value-based pricing in the market, and how different pricing models such as bundled payments or accountable care organizations impact risk factors.

December 28th 2013

Presentation 7: Where Does HEOR Fit in the Oncology Model?

Scott D. Ramsey, MD, PhD

According to Dr Ramsey, both the Health Economics Outcomes Research (HEOR) model and the pharmaceuticals pricing model in the United States are broken. He says: Unless we, as a community, figure out a way to use health economics in our decision making, we are not going to stop this train of unsupportable price increases in pharma.

December 28th 2013

Discussion 6: Nextâ€Generation Genetic Sequencing in Oncology: Ready for Prime Time?

Ira M. Klein, MD, MBA, FACP Michael Kolodjiez, MD Lee N. Newcomer, MD, MHA John L. Fox, MD, MHA Jerry Conway

Mr Klein leads another discussion with Michael Kolodjiez, MD, Lee N. Newcomer, MD, MHA, John L. Fox, MD, MHA, and Jerry Conway. The panel responds to whether there are gaps in targeted gene analyses. They also discuss other issues including bioinformatics, and how payers, providers, and pharmacists might collaborate on improving care through genetic sequencing.

December 28th 2013

Presentation 6: The Present (and Future) of Genetic Profiling in Oncology

Jerry Conway

Jerry Conway provides a DNA-centric view of organizing treatment plans with respect to the use of some advances in genomic technology.

December 28th 2013

Discussion 5: Companion Diagnostics in Targeted Treatments

Ira M. Klein, MD, MBA, FACP Jan Berger, MD, MJ Mike Kolodziej, MD

Dr Klein moderates this discussion, including co-editor in chief of The American Journal of Pharmacy Benefits Dr Jan Berger. The panel addresses a variety of topics as they relate to companion diagnostics in targeted treatments. Panelists respond to issues such as who should take responsibility in genetic counseling to ensure that patients have the best experience possible-whether it be in person or telephonic. Other topics covered in this discussion include appropriate consumerism in this space, the employer's role in genetic counseling, and how medical professionals are being trained or educated about these processes.

December 28th 2013

Presentation 5: Payer Perspectives on Genetic Counseling

Karen Lewis, MS, MM, CGC

Karen uses this session to analyze payer perspectives in genetic counseling. She describes the process involved with genetic counseling and the role of the counselor. She notes that the path to becoming a genetic counselor can often be more rigorous than in other specialties. Ms Lewis also discusses the surge of interest that genetic counseling has seen in recent years.

December 28th 2013

Presentation 4: An Update on Clinical Pathways

Bruce A. Feinberg, DO

Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, Clinical Pathways, begins this next segment from a different perspective.

...

165 166 167 168 169 170 171 172 173

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions